ankyrin repeat and SOCS box containing 9 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored ASB9P1 profile across patient tissues and cancer cell-line models. ASB9P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ASB9P1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ASB9P1 RNA expression shows 15,610 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where ASB9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB9P1 survival associations across molecular data types. ASB9P1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB9P1 RNA expression–survival associations across cancer types. High ASB9P1 expression shows unfavorable associations in BLCA and UVM, but favorable associations in LUAD, HNSC, BRCA and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ASB9P1 RNA expression.
This table summarizes ASB9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ASB9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB9P1 shows lower tumor expression in LUSC, LUAD and THCA and higher tumor expression in KIRC, LIHC and UCEC. The KIRC box plot shows higher ASB9P1 RNA expression in tumor versus normal tissue (log2 FC = +0.859, t-test p < 0.001).
This table shows molecular features associated with ASB9P1 in patient tissues and cancer cell lines. In patient samples, ASB9P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
